Not logged in Share Save
Share Save
Efficacy and Safety of Selective RET Inhibitors in Patients with Advanced Hereditary Medullary Thyroid Carcinoma Hamidi, Sarah; Yedururi, Sireesha; Hu, Mimi I.; Busaidy, Naifa L.; Sherman, Steven I.; Jimenez, Camilo; Grubbs, Elizabeth G.; Maniakas, Anastasios; Zafereo, Mark E.; Subbiah, Vivek; Waguespack, Steven G. Share Save
Glycemic control in diabetic patients improved overall lung cancer survival across diverse populations Wu, Wayne Y.; Luke, Brian; Wu, Xiao-Cheng; Lee, J. Jack; Yi, Yong; Okpechi, Samuel C.; Gause, Barry; Mehta, Paras; Sherman, Steven, I; Ochoa, Augusto; Dmitrovsky, Ethan; Liu, Xi Share Save
Next-Generation Sequencing in Sporadic Medullary Thyroid Cancer Patients: Mutation Profile and Disease Aggressiveness Shirali, Aditya S.; Hu, Mimi, I; Chiang, Yi-Ju; Graham, Paul H.; Fisher, Sarah B.; Sosa, Julie Ann; Perrier, Nancy; Brown, Spandana; Holla, Vijaykumar R.; Dadu, Ramona; Busaidy, Naifa; Sherman, Steven, I; Cabanillas, Maria; Waguespack, Steven G.; Zafereo, Mark E.; Grubbs, Elizabeth G. Share Save
Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer Subbiah, Vivek; Gouda, Mohamed A.; Iorgulescu, J. Bryan; Dadu, Ramona; Patel, Keyur; Sherman, Steven; Cabanillas, Maria; Hu, Mimi; Castellanos, Luz E.; Amini, Behrang; Meric-Bernstam, Funda; Shen, Tao; Wu, Jie Share Save
Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-RefractoryDifferentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study Capdevila, Jaume; Krajewska, Jolanta; Hernando, Jorge; Robinson, Bruce; Sherman, Steven I.; Jarzab, Barbara; Lin, Chia-Chi; Vaisman, Fernanda; Hoff, Ana O.; Hitre, Erika; Bowles, Daniel W.; Williamson, Denise; Levytskyy, Roman; Oliver, Jennifer; Keam, Bhumsuk; Brose, Marcia S. Share Save
Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who progressed after prior VEGFR-targeted therapy: Outcomes from COSMIC-311 by BRAF status Brose, M. S.; Keam, B.; Robinson, B.; Sherman, S.; Krajewska, J. A.; Lin, C-C.; Vaisman, F.; Hoff, A. O.; Hitre, E.; Bowles, D. W.; Ngamphaiboon, N.; Guo, X.; Zhang, F.; Schwickart, M.; Williamson, D. S.; Curran, D.; Berry, N.; Capdevila Castillon, J. Share Save
Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial Brose, Marcia S.; Robinson, Bruce G.; Sherman, Steven, I; Jarzab, Barbara; Lin, Chia-Chi; Vaisman, Fernanda; Hoff, Ana O.; Hitre, Erika; Bowles, Daniel W.; Sen, Suvajit; Oliver, Jennifer W.; Banerjee, Kamalika; Keam, Bhumsuk; Capdevila, Jaume Share Save
Share Save
Impact of baseline tumor burden on overall survival in patients with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib in the SELECT global phase 3 trial Kiyota, Naomi; Tahara, Makoto; Robinson, Bruce; Schlumberger, Martin; Sherman, Steven, I; Leboulleux, Sophie; Lee, Eun Kyung; Suzuki, Takuya; Ren, Min; Fushimi, Kazuma; Wirth, Lori J. Share Save
Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who have progressed after prior VEGFR-targeted therapy: Updated results from the phase III COSMIC-311 trial and prespecified subgroup analyses by prior therapy Capdevila, J.; Robinson, B.; Sherman, S. I.; Jarzab, B.; Lin, C-C.; Vaisman, F.; Hoff, A. O.; Hitre, E.; Bowles, D. W.; Sen, S.; Patel, P.; Oliver, J.; Keam, B.; Brose, M. S. Share Save
Impact of baseline tumor size on overall survival in patients with RR-DTC treated with lenvatinib (SELECT) Kiyota, Naomi; Tahara, Makoto; Robinson, Bruce; Schlumberger, Martin; Sherman, Steven; Leboulleux, Sophie; Lee, Eun Kyung; Suzuki, Takuya; Ren, Min; Fushimi, Kazuma; Wirth, Lori Share Save
Correlation of Performance Status and Neutrophil-Lymphocyte Ratio with Efficacy in Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Lenvatinib Taylor, Matthew H.; Takahashi, Shunji; Capdevila, Jaume; Tahara, Makoto; Leboulleux, Sophie; Kiyota, Naomi; Dutcus, Corina E.; Xie, Ran; Robinson, Bruce; Sherman, Steven; Habra, Mouhammed Amir; Elisei, Rossella; Wirth, Lori J. Share Save
Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study Cascone, T.; Sacks, R. L.; Subbiah, I. M.; Drobnitzky, N.; Piha-Paul, S. A.; Hong, D. S.; Hess, K. R.; Amini, B.; Bhatt, T.; Fu, S.; Naing, A.; Janku, F.; Karp, D.; Falchook, G. S.; Conley, A. P.; Sherman, S., I; Meric-Bernstam, F.; Ryan, A. J.; Heymach, J., V; Subbiah, V Share Save
ONC201 Shows Potent Anticancer Activity Against Medullary Thyroid Cancer via Transcriptional Inhibition of RET, VEGFR2, and IGFBP2 Bagheri-Yarmand, Rozita; Dadu, Ramona; Ye, Lei; Jebaraj, Yaashmin Shiny; Martinez, Jade A.; Ma, Junsheng; Tarapore, Rohinton S.; Allen, Joshua E.; Sherman, Steven, I; Williams, Michelle D.; Gagel, Robert F. Share Save
Distant Metastases From Childhood Differentiated Thyroid Carcinoma: Clinical Course and Mutational Landscape Nies, Marloes; Vassilopoulou-Sellin, Rena; Bassett, Roland L.; Yedururi, Sireesha; Zafereo, Mark E.; Cabanillas, Maria E.; Sherman, Steven, I; Links, Thera P.; Waguespack, Steven G. Share Save
Share Save
Share Save
Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies Hegde, Aparna; Andreev-Drakhlin, Alexander Y.; Roszik, Jason; Huang, Le; Liu, Shuang; Hess, Kenneth; Cabanillas, Maria; Hu, Mimi, I; Busaidy, Naifa L.; Sherman, Steven, I; Dadu, Ramona; Grubbs, Elizabeth G.; Ali, Siraj M.; Lee, Jessica; Elamin, Yasir Y.; Simon, George R.; Blumenschein, George R., Jr.; Papadimitrakopoulou, Vassiliki A.; Hong, David; Meric-Bernstam, Funda; Heymach, John; Subbiah, Vivek Share Save
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png)
THYROID.png)
OAAI
.png){kind=icon}
Share.png){kind=icon}
Save